Repros Updates Androxal(R) Global Regulatory Status

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Repros Updates Androxal(R) Global Regulatory Status
  • Full response to November meeting submitted to FDA
    • Repros believes all FDA questions positively addressed
  • Company expects contract organization to officially submit NDA to FDA during first quarter of 2015
  • Teleconference held with FDA to discuss Environmental Assessment requirements for NDA
    • Repros will conduct non-clinical environmental studies during the NDA review
  • Company believes there are no refuse to file issues for its NDA
  • Company contracts EU regulatory consultant to prepare European filings for Androxal ®

THE WOODLANDS, Texas, Dec. 29, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq: RPRX ) today updated the regulatory status for its drug, Androxal ® . Androxal ® is an oral therapy for the treatment of low testosterone due to secondary hypogonadism. Repros believes testosterone deficiency is linked to obesity in the majority of men that suffer from the disorder. In secondary hypogonadism associated with obesity, estrogen suppresses pituitary secretions of important hormones that are necessary for testosterone production by the testes. Androxal ® is an anti-estrogen and acts centrally to restore pituitary secretions and, thereby, restores normal testosterone production in the body.

On November 5, 2014, the Company received guidance from the FDA regarding its NDA submission for Androxal ® . During the second half of December the Company submitted a complete response to the guidance that the FDA provided. The Company believes it will have all documents to the contract organization assisting with the electronic filing of the NDA early in 2015 so that the dossier can be filed by the end of the first quarter 2015.

The Company had a follow-up discussion with the Agency regarding the Environmental Assessment requirements for the NDA. The FDA noted that commitment to perform the appropriate non-clinical experiments during the NDA review period would be considered sufficient for filing.

Overall, the Company believes there are no refuse to file issues for its NDA.

Lastly, the Company has engaged a European regulatory consultant, to convert the Company's Androxal ® NDA to a suitable dossier for EU filing. Based on the current schedule provided by the consultant, the Company believes that the dossier will be submitted in the EU in the first quarter of 2016.

In all jurisdictions the Company is seeking a New Chemical Entity status for Androxal ® .

About Repros Therapeutics Inc. ®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to planned clinical studies and the timing and nature of the results thereof, the timing of the Company's expected filing of an NDA for Androxal ® and the timing of the submission of an EU filing for Androxal ® . Such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including the ability to have success in the clinical development of the Company's technologies, the reliability of interim results to predict final study outcomes, the ability to protect the Company's intellectual property rights and such other risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com .

Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 105

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 228

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 29

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 28

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
2GenPen's Patent Push: Transforming Credit Analysis

Updated Category News Views 7

Changing the Game in Credit Analysis When you hear about a company snagging a patent, it's usually a big whoop-de-do; but 2GenPen's latest achievement is making some serious waves. This isn't some 'pat-yourself-on-the-back' sort of news – it's got teeth in the world of finance. These folks just locked down their second U.S. patent, number 12,784,096, and it's all about...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 131

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Innovation: Schneider Electric's Climate Tech Event

Updated Category News Views 170

Exploring the Excitement of the Climate Tech in the City Event The Climate Tech in the City event embodies the spirit of innovation, uniting key players in the climate technology sector. Leading organizations like Schneider Electric are at the forefront, showcasing groundbreaking advancements and sustainable practices. This year's gathering promises a vibrant day filled...

Continue Reading
Ouster Transforms Chattanooga into a Smart Traffic Hub

Updated Category News Views 404

Ouster's Groundbreaking Initiative in Smart Traffic Management In a significant development for urban traffic management, Ouster, Inc. (NASDAQ: OUST), recognized for its state-of-the-art lidar sensors, has launched a transformative project in Chattanooga. This venture stands out as the largest lidar-enabled traffic system in the United States, boasting a remarkable...

Continue Reading
Bicara Therapeutics Business Highlights and Q1 2025 Financial Review

Updated Category News Views 520

Bicara Therapeutics Announces Key Developments and Q1 2025 Financial Results Latest data from ongoing clinical trials to be showcased at upcoming conferences. Strong financial position enables sustained development through 2029. Bicara Therapeutics Inc. (Nasdaq: BCAX), a pioneering clinical-stage biopharmaceutical firm, focuses on delivering groundbreaking bifunctional...

Continue Reading
IO Biotech Gears Up for December Conferences: Insights and Highlights

Updated Category News Views 148

IO Biotech Prepares for Key Investor Conferences IO Biotech, a trailblazer in developing groundbreaking immune-modulatory cancer vaccines, is set to join two prominent investor events this December. The company, listed under NASDAQ: IOBT, is known for its innovative approach in the biopharmaceutical industry, particularly in creating off-the-shelf therapeutic cancer...

Continue Reading
Cardinal Energy Secures $40 Million Through Latest Debenture Offering

Updated Category News Views 267

Cardinal Energy Ltd. Announces a Major Offering Cardinal Energy Ltd. is excited to inform investors about its latest initiative aimed at raising funds through a significant offering. The company has entered into an agreement with a selected group of underwriters who will help facilitate the sale of $40 million in senior subordinated unsecured debentures. This strategic...

Continue Reading